Why Novo Nordisk Stock Just Popped
- - Why Novo Nordisk Stock Just Popped
Rich Smith, The Motley FoolFebruary 9, 2026 at 11:29 PM
0
Key Points -
Hims & Hers advertised a $49 Wegovy lookalike pill Thursday -- then on Saturday said it won't sell it.
Both the FDA and Novo Nordisk have objected to what Hims & Hers is doing.
10 stocks we like better than Novo Nordisk ›
Novo Nordisk (NYSE: NVO) is taking investors on another rollercoaster ride.
Last week, shares of the Danish pharmaceuticals stock tumbled as much as 27% on news that compounded pharmaceuticals firm Hims & Hers Health (NYSE: HIMS) would begin selling its own version of Novo's new Wegovy GLP-1 weight loss pill for just $49 per month.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Over the weekend, though, Hims announced it will in fact not sell the knockoff Wegovy pill. Nnow Novo Nordisk stock is bouncing back, up 3% through 12:15 p.m. ET.
GLP-1 Semaglutide injector pens in a box.
Image source: Getty Images.
Hims & Hers surrenders. Novo Nordisk sues.
Of course, there's a bit more to the story than that.
Novo wasn't pleased with Hims' announcement. After all, Hims' mooted price would undercut Novo's $149-a-month price for Wegovy in pill form -- and its $199 price for injectable Ozempic. Novo threatened to sue Hims for patent infringement Friday.
That same day, the Food and Drug Administration said it would crack down on Hims & Hers, potentially cutting off access to ingredients Hims needs to manufacture Wegovy (Ozempic) copycat pills, or by seizing Hims & Hers products.
Then, this morning, Novo followed through on its threat and filed in federal court for a permanent injunction against Hims & Hers selling any drugs that violate its "'343 Patent" on "semaglutide and the pharmaceutical products containing it." If Novo wins this lawsuit, Hims could be forbidden from selling both Ozempic copycats and Wegovy lookalikes, in pill or in injectable form.
What this means for Novo Nordisk stock
The outcome of litigation is never certain, but Novo appears to have the FDA on its side in this fight, and that's a good ally to have. Hims and Hers' decision to quickly cave on selling its pill further illustrates the strength of Novo's position.
Today's a good day to own Novo Nordisk stock.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,299!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,136,601!*
Now, it’s worth noting Stock Advisor’s total average return is 914% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 9, 2026.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Source: “AOL Money”
